JAMA Internal Medicine

JULY 14, 2024

This cohort study evaluates marketing payments from pharmaceutical and medical device manufacturers to physician trainees before and after fellowship graduation.

Cardiology 54

Cardiology Manufacturing Marketing 54

XTalks

JANUARY 22, 2025

The heart and vascular medication market continues to be a critical focus area for pharma companies, with billions of dollars in sales generated annually. However, challenges such as patent expirations, generic competition and pricing pressures continue to shape the market landscape. Eliquis (Apixaban) Eliquis 2023 sales :$12.21

Sales 104

Sales FDA Approval Drugs Marketing 104

Pharmaceutical Technology

JUNE 14, 2023

At market open, shares in Blue Water surged 90% higher than the previous day’s (13 June) market close. The company has a market cap of $20m. Blue Water will now also have marketing and distribution rights to Otovel and Cetraxal – both ear infection treatments. The agreement includes an $8.5m

FDA Approval 130

FDA Approval Cardiology Marketing Vaccine 130

Pharma Marketing Network

FEBRUARY 19, 2025

Introduction Email marketing remains one of the most powerful tools for pharma brands , helping reach healthcare professionals (HCPs), patients, and stakeholders with tailored messaging. But email marketing campaigns in the pharmaceutical industry come with unique challenges regulatory restrictions, privacy concerns, and engagement barriers.

Compliance 72

Compliance Marketing Branding Regulation 72

XTalks

FEBRUARY 12, 2025

Current PCSK9 inhibitors on the market include Regenerons monoclonal antibody Praluent (alirocumab), Amgens Repatha (evolocumab) and Novartiss Leqvio (inclisiran), which is a small RNA interference (siRNA) therapy designed to lower LDL-C. This gives lerodalcibep an edge to approved PCSK9 inhibitors.

Cardiology 59

Cardiology Trials Clinical Trials Clinical Trials 59

XTalks

DECEMBER 2, 2024

The US Food and Drug Administration (FDA) has approved AOP Health’s landiolol injection, marketed as Rapiblyk, for the treatment of atrial fibrillation (Afib) and atrial flutter in critical care settings. This approval marks Rapiblyk’s introduction to the US market after being available in Europe.

Trials 104

Trials Marketing FDA Approval Life Science 104

Worldwide Clinical Trials

JANUARY 6, 2025

Similarly, the EMAs PRIority MEdicine (PRIME) designation and conditional marketing authorization enable accelerated approval for drugs addressing critical and underserved medical needs, provided they meet stringent evidence requirements.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Genetics 130

Pharma Marketing Network

FEBRUARY 27, 2025

Introduction In todays digital-first world, content marketing campaigns are no longer optional for pharmaceutical brands. Imagine content marketing as the heartbeat of a pharma brands digital presence. But when done right, content marketing campaigns create lasting relationships, drive awareness, and improve patient outcomes.

Branding 52

Branding Marketing Compliance Pharma Companies 52

Drug Channels

NOVEMBER 28, 2023

In this issue: A reality check on Express Scripts’ purported “cost-based” pharmacy network Mark Cuban explains how and why the PBM market will change Why two drug prices are better than one Pharmacists sing the retail pharmacy shakeout blues Plus, two Philly legends meet at a cardiology conference!

Pharmacy 97

Pharmacy Drugs Cardiology Marketing 97

XTalks

APRIL 7, 2022

The LEADLESS II–Phase 2 study was published in the Journal of the American College of Cardiology: Clinical Electrophysiology. According to a report by Persistence Market Research, the market for leadless pacemakers was estimated to be $29.4 The study showed that the implant success was 98 percent and 83.2

FDA Approval 105

FDA Approval Clinical Trials Clinical Trials Cardiology 105

XTalks

NOVEMBER 26, 2024

A Marketing Authorization Application has been submitted to the European Medicines Agency (EMA), with a decision anticipated in 2025. The availability of a treatment that addresses both survival and quality of life represents a long-awaited milestone for patients and their caregivers.

Genetic Disease 105

Genetic Disease Genetics Protein Clinical Development 105

pharmaphorum

JUNE 25, 2021

But Dr Craig Granowitz, chief scientific officer of cardiology drug developer Amarin, says that this is only the tip of the iceberg when it comes to the devastating impact of CVD on global populations. “In But one of the biggest issues in changing people’s expectations and improving outcomes is “apathy”, he says.

Cardiology 100

Cardiology Drugs Development Clinical Trials 100

BioTech 365

SEPTEMBER 2, 2020

NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, … Continue reading → SOUTH JORDAN, Utah, Sept.

Radiology 40

Radiology Cardiology Manufacturing Marketing 40

pharmaphorum

JULY 14, 2022

The legacy product now lies outside Bayer’s core areas of cardiology, oncology, haematology, ophthalmology, women’s health and radiopharmaceuticals, and the funds raised from the sale will support the “ongoing transformation of Bayer’s pharma business to focus on key areas of future medical innovation”, said the company.

Drugs 97

Drugs Sales Pharma Companies Cardiology 97

pharmaphorum

JUNE 17, 2022

The licensing deal took place as AZ was trimming down its pipeline to focus its R&D activities on the core areas of cardiology, diabetes and neurology, and recovering from a series of patent expiries that hit its revenues. Since then it has bounced back dramatically, thanks to fast-growing drugs for cancer and heart disease.

Licensing 81

Licensing Licensing Cardiology Antibody 81

pharmaphorum

FEBRUARY 26, 2021

Following World War II, Ethicon’s market share in surgical sutures rose from 15% to 70% worldwide. Today, Janssen is one of the world’s leading research-based pharma companies and markets prescription medicines in the areas of gastroenterology, women’s health, mental health, neurology and HIV/AIDS, to name a few. “Dr

Sales 126

Sales Production Pharma Companies Marketing 126

pharmaphorum

FEBRUARY 25, 2022

. “While Jardiance may not be effective in all patients with heart failure, this approval is a significant step forward for patients and our understanding of heart failure,” says Norman Stockbridge, MD, PhD, director of the Division of Cardiology and Nephrology in the FDA’s Center for Drug Evaluation and Research.

FDA Approval 101

FDA Approval HR Cardiology Drugs 101

pharmaphorum

JUNE 22, 2021

AstraZeneca’s SGLT2 inhibitor Farxiga has been growing fast thanks to a first-in-class approval in heart failure, but will now have to share the market with Boehringer Ingelheim and Eli Lilly’s rival therapy Jardiance. . The FDA removed the boxed warning for those risks last year but the product hasn’t recovered commercially.

Sales 98

Sales Marketing FDA Approval Trials 98

Velocity Clinical Research

NOVEMBER 21, 2023

“I’m proud and excited to be a part of it.” Dr. Schenkenberger is especially proud of her clinical trial research work in heart health, noting most new drugs never make it to market. The site has 2 full-time investigators and cooperates closely with specialists for internal medicine, orthopedics, neurology, and cardiology.

Medicine 59

Medicine Cardiology Clinical Research Clinical Trials 59

XTalks

JULY 19, 2021

“We successfully brought a medical-grade test, analogs of which are billed by the big players anywhere from $1,500 – $10,000, to a price point more accessible to the consumer market at $249.”. Bisignano added that, “It is time we finally made a medical-grade genetic test available as a proactive, preventative tool.

Genetics 98

Genetics Genomics Genome Gene 98

pharmaphorum

FEBRUARY 17, 2022

Bristol-Myers Squibb has new data backing up the value of mavacamten for obstructive hypertrophic cardiomyopathy (HCM), as it waits for a delayed verdict on its marketing application for the drug, acquired as part of its $13.1 billion takeover of MyoKardia in 2020.

Cardiology 59

Cardiology Trials Marketing Drugs 59

Velocity Clinical Research

DECEMBER 6, 2023

In addition to being one of Poland’s top recruiting sites in cardiology trials, ClinMedica also recruits patients across a broad range of therapeutic areas involving ambulatory medicine. Gackowska has led international teams dedicated to clinical trials management, product launch, market access, marketing, and sales.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

pharmaphorum

AUGUST 18, 2021

Eli Lilly and Boehringer Ingelheim have claimed FDA approval for their diabetes therapy Jardiance in heart failure with reduced ejection fraction (HFreF), setting up a market tussle with AstraZeneca’s Farxiga. Sales have rocketed ever since, climbing 30% to almost $2 billion last year, and 60% to $1.36 billion in the first half of 2021.

Cardiology 52

Cardiology Sales Marketing FDA Approval 52

Delveinsight

AUGUST 3, 2021

DelveInsight’s analysis in the report titled, DelveInsight’s Chronic Pain associated with Painful Diabetic Neuropathy – Epidemiology Forecast – 2030 Market Insights, Competitive Landscape and, Market Forecast – 2026 , the market size of the Senza Omnia system is estimated to increase to around USD 3,500 million by 2026.

FDA Approval 98

FDA Approval Marketing Cardiology Production 98

pharmaphorum

JULY 6, 2021

Novartis has tried to get its marketing application for high cholesterol therapy inclisiran in the US back on track, after the FDA rejected it last year, by changing the factory that makes the drug.

RNA 105

RNA Manufacturing Sales Drugs 105

pharmaphorum

JANUARY 5, 2021

An IQVIA survey to Neurology, Cardiology, Rheumatology, Dermatology and Ophthalmologists in June 2020 across the lead five European countries showed an average of 30% of patients either “no shows” or still waiting for treatment that was delayed. The market access lever is more heavily applied in Europe than the US.

Sales 105

Sales Marketing Production Vaccine 105

Medical Xpress

DECEMBER 21, 2022

Identifying early risks and treatments among children and mothers, continued health disparities and finding new ways to use medications already on the market are among some of the significant scientific research developments in the fight against heart disease and stroke that emerged in 2022.

Research 97

Research Marketing Development Cardiology 97

The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) in January 2021 and was recommended for marketing authorization by the Committee for Medicinal Products for Human Use (CHMP) in the EU in May 2021. Additionally, it has been submitted for marketing authorization in China, as well as multiple other countries worldwide. Kenilworth, NJ, USA).

Cardiology 52

Cardiology Production Development Medicine 52

pharmaphorum

JULY 7, 2021

The top-line data sets up a possible market clash with Novartis, which secured the first FDA approval for a drug treatment for HFpEF in February, although the label for its Entresto (sacubitril/valsartan) drug says that its benefits are more evident in patients with reduced ejection fraction.

Sales 52

Sales Cardiology FDA Approval Trials 52

pharmaphorum

MARCH 15, 2022

Major societies such as the European Society of cardiology (ESC) reported a 177% increase in attendees for its 2020 annual congress : 77,350 virtual attendees (logged-on) 2020 cf 27,946 physical attendees 2019. One important caveat here is that delegate registration fees were waived. Figure 1 What doctors say about virtual events . .

Doctors 105

Doctors Doctor Cardiology Allergies 105

XTalks

JUNE 26, 2023

According to Surmodics, SurVeil DCB is approved to be marketed and sold in the US for percutaneous transluminal angioplasty of de novo or restenotic lesions in femoral and popliteal arteries having reference vessel diameters of 4 mm to 7 mm.

FDA Approval 96

FDA Approval Drugs Sales In-Vitro 96

The Pharma Data

DECEMBER 14, 2020

The launch enables physicians to reach previously inaccessible areas of the heart for procedure mapping, by making available the smallest diagnostic catheter in the Canadian electrophysiology market. The EPstar catheters are widely used in the Japanese electrophysiology market and were launched in the United States market in 2019.

Cardiology 52

Cardiology Manufacturing Marketing Production 52

pharmaphorum

OCTOBER 2, 2020

They have also been designed to improve the speed and consistency with which commercial research is delivered in the NHS and, by making it easier and quicker to deliver commercial research, the NPRCs will improve the UK’s competitiveness in the global market.

Clinical Trials 92

Clinical Trials Clinical Trials Clinical Research Life Science 92

pharmaphorum

MAY 18, 2021

billion acquisition of Corvidia Therapeutics in June last year, The deal saw the firm begin to explore new markets after making its name in diabetes, a market which is being squeezed by pricing pressures. Data were announced at the virtual American College of Cardiology annual conference and published simultaneously in The Lancet.

Drugs 52

Drugs Cardiology Trials Clinical Trials 52

XTalks

AUGUST 22, 2022

This month, MolecuLight has secured financing from BDC Capital and iGan Ventures to support the company’s global expansion to meet the increasing market demand for their i :X and DX devices. Orthopaedics have X-ray, cardiology has echocardiography, cancer has ultrasound, PET, CT and MRI. Read on to learn more!

Bacteria 111

Bacteria Containment Sales Cardiology 111

Delveinsight

JULY 22, 2021

The decision gave Bayer complete control of BlueRock’s cell therapy pipeline, headed by DA01 and spanning various diseases in the neurology , cardiology , and immunology categories. To do so, Omniscient will utilize the financing to expand market access for its existing brain-mapping platforms, in part by increasing its global sales team.

Cardiology 98

Cardiology Development Engineer Clinical Trials 98

pharmaphorum

AUGUST 13, 2020

The cholesterol-lowering drug has been classed as a breakthrough therapy for homozygous familial hypercholesterolaemia (HoFH) by the FDA, which is due to deliver a decision on the marketing application by 11 February after a truncated six-month review.

Drugs 52

Drugs Antibody Sales Cardiology 52